High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease (Q51778180)

12 April 2018

title

High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease (English)

1 reference

12 April 2018

0 references

1 reference

1 reference

12

1 reference

12 April 2018

author name string

Jens Kastrup

1

1 reference

12 April 2018

Julia S Johansen

2

1 reference

12 April 2018

Per Winkel

3

1 reference

12 April 2018

Jørgen Fischer Hansen

4

1 reference

12 April 2018

Per Hildebrandt

5

1 reference

12 April 2018

Gorm Boje Jensen

6

1 reference

12 April 2018

Christian M Jespersen

7

1 reference

12 April 2018

Erik Kjøller

8

1 reference

12 April 2018

Hans Jørn Kolmos

9

1 reference

12 April 2018

Inga Lind

10

1 reference

12 April 2018

Henrik Nielsen

11

1 reference

12 April 2018

CLARICOR Trial Group

13

1 reference

12 April 2018

publication date

6 March 2009

1 reference

12 April 2018

published in

European Heart Journal

1 reference

12 April 2018

volume

30

1 reference

12 April 2018

issue

9

1 reference

12 April 2018

page(s)

1066-1072

1 reference

12 April 2018

Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease

cites work

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

A chitinase-like protein in the lung and circulation of patients with severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

Serum YKL-40, a new prognostic biomarker in cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

Serum YKL-40 levels in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

Inflammation as a cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

Use of multiple biomarkers to improve the prediction of death from cardiovascular causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/EURHEARTJ/EHP049

21 January 2018

Identifiers

DOI

10.1093/EURHEARTJ/EHP049

1 reference

12 April 2018

1 reference

12 April 2018